The role of BCL-2 family proteins and therapeutic potential of BH3-mimetics in malignant pleural mesothelioma
Surein Arulananda, Erinna F Lee, W Douglas Fairlie, Thomas John
Expert Review of Anticancer Therapy | TAYLOR & FRANCIS LTD | Published : 2020
Introduction: With limited recent therapeutic changes, malignant pleural mesothelioma (MPM) is associated with poor survival and death within 12 months, making it one of the most lethal malignancies. Due to unregulated asbestos use in developing countries and home renovation exposures, cases of MPM are likely to present for decades. As MPM is largely driven by dysregulation of tumor suppressor genes, researchers have examined other mechanisms of subverting tumor proliferation and spread. Over-expression of pro-survival BCL-2 family proteins impairs cells from undergoing apoptosis, and BH3-mimetics targeting them are a novel treatment option across various cancers, though have not been widel..View full abstract
Awarded by National Health and Medical Research Council of Australia
Awarded by Australian Research Council
Awarded by Victorian Cancer Agency
Support for this work was provided by a National Health and Medical Research Council of Australia Project Grant (GNT1157551) to W.D.F. and T. J. S.A. is the recipient of a La Trobe University Post Graduate Research Scholarship and a Lung Foundation Australia Grant-in-Aid. E.F.L. is a recipient of fellowships from the Australian Research Council (Future Fellowship FT150100212) and the Victorian Cancer Agency (Mid-Career Fellowship MCRF19045).